Immatics (NASDAQ:IMTX - Get Free Report) had its price target reduced by Bank of America from $16.00 to $15.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Bank of America's price target indicates a potential upside of 92.06% from the stock's previous close.
Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a report on Thursday, September 5th. Piper Sandler began coverage on Immatics in a report on Monday, October 7th. They issued an "overweight" rating and a $19.00 target price on the stock.
Read Our Latest Research Report on IMTX
Immatics Trading Down 0.1 %
NASDAQ IMTX traded down $0.01 on Tuesday, reaching $7.81. The company's stock had a trading volume of 940,219 shares, compared to its average volume of 498,391. The firm has a market cap of $932.17 million, a PE ratio of -8.78 and a beta of 0.78. Immatics has a 52 week low of $7.65 and a 52 week high of $13.77. The business has a 50-day moving average price of $10.18 and a 200 day moving average price of $11.22.
Institutional Investors Weigh In On Immatics
Several hedge funds and other institutional investors have recently made changes to their positions in IMTX. Price T Rowe Associates Inc. MD boosted its holdings in Immatics by 38.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company's stock valued at $33,899,000 after acquiring an additional 891,191 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of Immatics in the 2nd quarter valued at about $904,000. Frazier Life Sciences Management L.P. bought a new position in shares of Immatics in the 2nd quarter valued at about $13,392,000. abrdn plc acquired a new stake in shares of Immatics during the 3rd quarter worth approximately $2,657,000. Finally, Perceptive Advisors LLC raised its stake in shares of Immatics by 76.5% during the second quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company's stock worth $93,961,000 after buying an additional 3,503,750 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
